Jazz (JAZZ) Q2 Revenue Rises 2%
Jazz Pharmaceuticals (NASDAQ:JAZZ) is a global biopharmaceutical company focused on innovative therapies for neuroscience and rare oncology diseases. On August 5, 2025, it reported second quarter results for fiscal 2025. The company announced GAAP revenue of $1.05 billion, rising 2% from the same period last year, but slightly under the $1.05 billion analyst estimate (GAAP revenue). Non-GAAP earnings per share (EPS) were $(8.25), falling short of the consensus non-GAAP EPS estimate of $(7.61), mainly because of a $905.4 million one-time charge linked to the acquisition of Chimerix and its pipeline drug dordaviprone. While Neuroscience product sales showed positive trends, especially from its key Xywav and Epidiolex franchises, some oncology products continued to face competitive and protocol-driven headwinds. Overall, the period highlighted steady top-line growth, heavy non-recurring expenses, and a continued pivot toward portfolio diversification.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Jazz Pharmaceuticals develops and markets medicines primarily for neurological disorders and rare cancers. Its main commercial products address sleep disorders, seizure-related diseases, and several types of cancer. The company’s best-known drugs include Xywav (a low-sodium oxybate oral solution for narcolepsy and idiopathic hypersomnia), Epidiolex (cannabidiol, a plant-derived medicine for rare forms of epilepsy), and key oncology franchises such as Rylaze (for leukemia) and Zepzelca (for small cell lung cancer).
Source Fool.com
